{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:58:39Z","timestamp":1781110719011,"version":"3.54.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009576","name":"Nantong Municipal Commission of Health and Family Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009576","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>CD19-directed CAR T-cell therapy is a breakthrough immunotherapy for B-cell malignancies. However, CD19 loss-mediated relapsed\/refractory disease continues to pose a significant challenge, highlighting the urgent need for CAR T cells targeting alternative antigens. To address this issue, we developed a CD20-directed CAR T incorporated with an additional CD30-directed binder to enhance cytotoxicity toward cancer cells. Here, we report that a patient with bulky transformed follicular lymphoma was successfully treated with CD20\/CD30-directed CAR-T cells. The patient received two doses of anti-CD20\/CD30-CAR-T therapy administered one month apart. Complete metabolic remission was achieved 1 month after the first infusion without evidence of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). The second dose was given as a consolidation therapy with sustained disease-free survival exceeding 12 months to date. The report underscores the promising therapeutic potential and safety profile of CD20\/CD30-directed CAR T-cell therapy.<\/jats:p><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.clinicaltrials.gov<\/jats:uri>, identifier NCT06756321.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1567149","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T10:36:13Z","timestamp":1746700573000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Bispecific CD20\/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin\u2019s lymphoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuejiao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaying","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosein","family":"Kouros-Mehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"Kte-X19 for relapsed or refractory adult B-cell acute lymphoblastic le ukaemia: phase 2 results of the single-arm, open-label, multicentre zu","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel car T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-hodgkin lymphoma (Zuma-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"Kte-X19 car T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (Transcend nhl 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 transcend fl study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 elara trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-cd19 car T-cell therapy: A descar-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0","article-title":"Car T cells with dual targeting of cd19 and cd22 in adult patients with recurrent or refractory B cell Malignancies: A phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of cd19 enables resistance to cart-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0831-z","article-title":"Frequent occurrence of cd19-negative relapse after cd19 car T and consolidation therapy in 14 tp53-mutated R\/R B-all children","volume":"34","author":"Pan","year":"2020","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem cd19\/cd20 car lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010930","article-title":"Cd19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27488","article-title":"C-car066, a novel fully human anti-cd20 car-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-cd19 car-T therapy: A phase I clinical study","volume":"99","author":"Li","year":"2024","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.05.001","article-title":"Cd20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory\/relapsed B-cell non-hodgkin lymphoma","volume":"24","author":"Cheng","year":"2022","journal-title":"Cytotherapy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1182\/blood-2023-175007","article-title":"Efficacy and safety of a third generation cd20 car-T (Mb-106) for treatment of relapsed\/refractory indolent B-cell non-hodgkin lymphoma: phase-1 results from a multicenter trial","volume":"142","author":"Shadman","year":"2023","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e68877ca","DOI":"10.1097\/01.HS9.0000971284.68877.ca","article-title":"P1097: cd20 car-T therapy with mb-106 for btk inhibitor-refractory waldenstr\u00d6m macroglobulinemia (Wm)\/lymphoplasmacytic lymphoma (Lpl) \u2013 single institution study","volume":"7","author":"Shadman","year":"2023","journal-title":"HemaSphere"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843720.23634.a9","article-title":"S207: efficacy and safety of a third generation cd20 cart (Mb-106) for treatment of relapsed\/refractory follicular lymphoma (Fl)","volume":"6","author":"Shadman","year":"2022","journal-title":"HemaSphere"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1376490","article-title":"Salvage cd20-sd-cart therapy in aggressive B-cell lymphoma after cd19 cart treatment failure","volume":"14","author":"Xue","year":"2024","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/299065a0","article-title":"Production of a monoclonal antibody specific for hodgkin and sternberg-reed cells of hodgkin\u2019s disease and a subset of normal lymphoid cells","volume":"299","author":"Schwab","year":"1982","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1006\/smim.1998.0156","article-title":"Cd30: expression and function in health and disease","volume":"10","author":"Horie","year":"1998","journal-title":"Semin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/jci94306","article-title":"Clinical and immunological responses after cd30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01342","article-title":"Anti-cd30 car-T cell therapy in relapsed and refractory hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.858021","article-title":"Anti-pd-1 therapy enhances the efficacy of cd30-directed chimeric antigen receptor T cell therapy in patients with relapsed\/refractory cd30+ Lymphoma","volume":"13","author":"Sang","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-1365","article-title":"Autologous T cells expressing cd30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006959","article-title":"Patient-reported outcomes in cd30-directed car-T cells against relapsed\/refractory cd30+ Lymphomas","volume":"11","author":"Tschernia","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011470","article-title":"Transient responses and significant toxicities of anti-cd30 car T cells for cd30+ Lymphomas: results of a phase 1 trial","volume":"8","author":"Brudno","year":"2024","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-cd20, anti-cd19 car T cells for relapsed B cell Malignancies: A phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005278","article-title":"Optimized tandem cd19\/cd20 car-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc6401","article-title":"Trispecific cd19-cd20-cd22-targeting duocar-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models","volume":"13","author":"Schneider","year":"2021","journal-title":"Sci Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem cd19\/cd20 car therapy in refractory\/relapsed B-cell lymphoma: A single-arm, phase 1\u20132 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26718","article-title":"Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific lv20.19 car T-cells","volume":"97","author":"Zurko","year":"2022","journal-title":"Am J Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020621","article-title":"Cd19\/cd22 targeting with cotransduced car T cells to prevent antigen-negative relapse after car T-cell therapy for B-cell all","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3892\/ijo.2023.5501","article-title":"Bispecific gpc3\/pd\u22121 car\u2212T cells for the treatment of hcc","volume":"62","author":"Li","year":"2023","journal-title":"Int J Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006239","article-title":"Il15 modification enables car T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in gbm","volume":"11","author":"Zannikou","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae126","article-title":"Il-13r\u03b12\/tgf-\u03b2 Bispecific car-T cells counter tgf-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma","volume":"26","author":"Hou","year":"2024","journal-title":"Neuro Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3891","article-title":"Chimeric antigen receptor T cells targeting cd19 and gcc in metastatic colorectal cancer: A nonrandomized clinical trial","volume":"10","author":"Chen","year":"2024","journal-title":"JAMA Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.06.007","article-title":"Blocking cd30 on T cells by a dual specific car for cd30 and colon cancer antigens improves the car T cell response against cd30(-) tumors","volume":"27","author":"Hombach","year":"2019","journal-title":"Mol Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.5858\/2001-125-1036-ceifl","article-title":"Cd30 expression in follicular lymphoma","volume":"125","author":"Gardner","year":"2001","journal-title":"Arch Pathol Lab Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.778407","article-title":"Frequency and extent of cd30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: A retrospective study of 167 cases","volume":"54","author":"Campuzano-Zuluaga","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-461848","article-title":"Cd30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the international dlbcl rituximab-chop consortium program study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-02242","article-title":"Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory dlbcl with variable cd30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second cd19-targeted car T-cell infusion for refractory B-cell Malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004483","article-title":"Efficacy of second car-T (Cart2) infusion limited by poor cart expansion and antigen modulation","volume":"10","author":"Holland","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90180-k","article-title":"Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for hodgkin\u2019s disease","volume":"68","author":"D\u00fcrkop","year":"1992","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/112.2.241","article-title":"Cd30 expression is common in mediastinal large B-cell lymphoma","volume":"112","author":"Higgins","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.5858\/2009-0463-rsr.1","article-title":"Primary mediastinal (Thymic) large B-cell lymphoma: A short review with brief discussion of mediastinal gray zone lymphoma","volume":"135","author":"Hutchinson","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1","article-title":"Car T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-22-0964","article-title":"Cd19\/cd20 bispecific chimeric antigen receptor (Car) in naive\/memory T cells for the treatment of relapsed or refractory non-hodgkin lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015795","article-title":"Cd19\/22 car T cells in children and young adults with B-all: phase 1 results and development of a novel bicistronic car","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific car-T cells targeting both cd19 and cd22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-022-00270-5","article-title":"A novel and efficient cd22 car-T therapy induced a robust antitumor effect in relapsed\/refractory leukemia patients when combined with cd19 car-T treatment as a sequential therapy","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp Hematol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1567149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T10:36:15Z","timestamp":1746700575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1567149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2025.1567149"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1567149","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"article-number":"1567149"}}